Centaur Capital Partners’s Harvard Bioscience HBIO Stock Holding History

Centaur Capital Partners’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-5,000	Closed	-$284K	–	34
2014 Q4	$284K	Sell	5,000 -22,160	-82%	-$1.06M	0.46%	25
2014 Q3	$1.11M	Sell	27,160 -2,840	-9%	-$131K	1.56%	27
2014 Q2	$1.36M	Buy	30,000 +1,500	+5%	+$63K	1.93%	21
2014 Q1	$1.35M	Buy	28,500 +2,500	+10%	+$114K	2.18%	19
2013 Q4	$1.22M	Buy	+26,000	New	+$1.14M	1.41%	25

Other funds holding HBIO

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Centaur Capital Partners's HBIO Position: Q1 2015 in Review

Centaur Capital Partners sold out of Harvard Bioscience (HBIO) in Q1 2015, closing a stake of 5,000 shares — an estimated $284K sold.

Centaur Capital Partners first reported a position in HBIO in Q4 2013 and held it in 5 quarters. The position peaked at $1.36M in Q2 2014. 79 funds tracked by Wall St. Rank hold HBIO as of Q1 2015.

Centaur Capital Partners reported no remaining Harvard Bioscience position as of Q1 2015 after selling out during the quarter.
Centaur Capital Partners sold 5,000 Harvard Bioscience shares in Q1 2015, an estimated $284K.
Centaur Capital Partners first reported a position in Harvard Bioscience in Q4 2013 and held it in 5 quarters.
Centaur Capital Partners's Harvard Bioscience position peaked at $1.36M in Q2 2014.
79 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2015.

Based on Centaur Capital Partners's 13F filing for Q1 2015, filed 15 May 2015.